RWCS | Feb 10-13, 2021 | Maui, HI | Virtual
ACR-SOTA | Mar 26-28, 2021 | New Orleans, LA
NKF | Apr 6-10, 2021 | Virtual
AWIR | Aug 12-15, 2021 | Hilton Head, SC
CCR East | Aug 12-15, 2021 | Destin, FL
CCR West | Sep 18-21, 2021 | Coronado, CA
ASN | Nov 2-7, 2021 | San Diego, CA
ACR | Nov 5-9, 2021 | San Francisco, CA
Presented By: Dr. Michelle Petri MD, MPH
Presented by: Dr. Michael E. Wechsler, MD, MMSc
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Phase II | Phase III | Phase IV |
---|---|---|---|
|
|||
SABLE: Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry |
NCT01729455 | ||
Belimumab Pregnancy Registry |
NCT01532310 | ||
BLISS-LN: Belimumab in Active Lupus Nephritis |
NCT01639339 | ||
|
|||
BLISS-BELIEVE: Belimumab Subcutaneous in Combination with Rituximab in Adult SLE |
NCT03312907 |
RHEUMATOID ARTHRITIS (RA) | Phase II | Phase III | Phase IV |
---|---|---|---|
|
|||
ContRAst-1: Otilimab vs Placebo and Tofacitinib in Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Methotrexate |
NCT03980483 | ||
ContRAst-2: Otilimab vs Placebo and Tofacitinib in Moderately to Severely Active RA who have Inadequate Response to Conventional Synthetic DMARDs |
NCT03970837 | ||
ContRAst-3: Otilimab vs Placebo and Sarilumab in Moderately to Severely Active RA with Inadequate Response to Biologic DMARDs and/or JAKI |
NCT04134728 | ||
Mechanistic Study of Otilimab Plus Methotrexate in Active Rheumatoid Arthritis Despite Treatment With DMARDs |
NCT02799472 (Phase IIa) |
||
Otilimab Plus Methotrexate in Active Moderate-Severe Rheumatoid Arthritis |
NCT02504671 (Phase IIb) |
INFLAMMATORY BOWEL DISEASE | Phase II | Phase III | Phase IV |
---|---|---|---|
|
|||
Study of anti-LAG3 in Ulcerative Colitis |
NCT03893565 |
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) |
Phase II | Phase III | Phase IV |
---|---|---|---|
VCRC-VPPRN EGPA Registry (Observational Study)* |
NCT00315380 (Observational) |
SJÖGREN’S SYNDROME | Phase II | Phase III | Phase IV |
---|---|---|---|
|
|||
Belimumab Subcutaneous and Intravenous Rituximab Co-Administered in Primary Sjögren’s Syndrome |
NCT02631538 |
SYSTEMIC SCLEROSIS | Phase II | Phase III | Phase IV |
---|---|---|---|
|
|||
Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis |
NCT03041025 |